January 9, 2024 by Ronald Piervincenzi
2024 Health care outlook: Ronald Piervincenzi, CEO, U.S. Pharmacopeia
January 22, 2024, Opinion, Pharmacy
In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The past year was significant for the pharmaceutical industry, as we witnessed major milestones and celebrated advancements in innovation. We saw an official end to the COVID-19 pandemic public health emergency and unlocked the potential
January 8, 2024 by Sandra Hanna
CEO, Health care outlook 2024: Sandra Hanna, Neighbourhood Pharmacies
January 8, 2024, Opinion, Pharmacy
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review. 2023 was a momentous year for community pharmacy in Canada. All provinces further expanded pharmacists’ scope of practice and/or increased
January 8, 2024 by Lee Ann Stember
CEO, Lee Ann Stember, NCPDP, president
January 8, 2024, Opinion, Pharmacy
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review We are, without a doubt, at a tipping point with the current state of pharmacy practice. Drug shortages, staffing shortages,
January 8, 2024 by Michael Hogue
APhA, CEO, Michael Hogue
January 8, 2024, Opinion, Pharmacy
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review. As the oldest national professional association for pharmacists, pharmacy technicians, student pharmacists and pharmaceutical scientists, the American Pharmacists Association touches
January 8, 2024 by Susan Cantrell
AMCP, CEO, Susan Cantrell
January 8, 2024, Opinion, Pharmacy
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review As we embark on a new year, there is value in taking a moment to reflect on the current state
March 16, 2015 by Chain Drug Review and Chain Drug Review
Andreas Rouvé, CEO, chief executive officer, Dave Lumley, Spectrum Brands Holdings
Supplier News
MIDDLETON, Wis. — Andreas Rouvé has been elected chief executive officer of Spectrum Brands Holdings Inc., succeeding Dave Lumley, who plans to retire from the company. Spectrum Brands said Monday that Rouvé, 53, is slated to take the CEO reins effective April 1. He has served as the consumer products company’s chief operating officer since
February 2, 2015 by John Schultz and Chain Drug Review
CEO, chief executive officer, Craig Wheeler, generic drug industry, Generic Pharmaceutical Association, GPhA, Hatch-Waxman Act, president, Ralph Neas
2015, Issue 02-02-2015, News, Pharmacy
WASHINGTON — Ralph Neas, president and chief executive officer of the Generic Pharmaceutical Association, has announced he will step down from his position in the fall. Neas has led GPhA since September 2011. During his remaining tenure, he will continue to serve as CEO until a successor is named and will work to ensure a
January 5, 2015 by Jeffrey Woldt and Chain Drug Review
Alliance Boots, CEO, chief executive officer, drug chain, Greg Wasson, Jeffrey Woldt, retail pharmacy, Stefano Pessina, Walgreens
2015, Issue 01-05-2015, Opinion
When the history of Walgreen Co. is written, Greg Wasson, who last month announced that he would step down as chief executive officer of the drug chain upon completion of its merger with Alliance Boots, will be seen as one of the company’s most consequential leaders. A product of the Walgreens system who joined the